Opinion

Amy Moore: BIG DEAL for those living with small cell lung cancer

Photo taken from LUNGevity Foundation/X

May 20, 2024, 13:49

Amy Moore: BIG DEAL for those living with small cell lung cancer

Amy Moore, VP of Global Engagement and Patient Partnerships, LUNGevity Foundation, shared a post by LUNGevity Foundation on X, adding the following:

“This is a BIG DEAL for those living with small cell lung cancer. Using “targeted immunotherapy” that tethers the cancer cell and a T cell (a type of immune cell), you can cause the cancer cell to burst. This is a new era for how researchers are approaching this and other cancers.”

Quoting LUNGevity Foundation’s post:

“FDA Accelerated Approval Alert!

The US Food and Drug Administration (FDA) announced the accelerated approval of tarlatamab-dlle (Imdelltra®) to treat patients with extensive-stage small cell lung cancer (SCLC). Learn more.”

Source: Amy Moore/X and LUNGevity Foundation/X
.

Accelerated Approval Amy Moore cancer cancer cell burst Cancer research extensive-stage SCLC FDA approval Imdelltra immunotherapy advances innovative therapy LUNGevity Foundation new cancer treatment OncoDaily Oncology SCLC treatment small cell lung cancer T cells Targeted Immunotherapy tarlatamab-dlle

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage